Canaccord Genuity Raises Beam Therapeutics Price Target to $79
Canaccord Genuity raised its price target on Beam Therapeutics to $79 per share from $78 and maintained its Buy rating.
Related stories
Viatris Commences Tender Offer to Acquire Pacira BioSciences
M impact | EQUITY | Oct 30, 2026, 01:03 PM UTC
BofA Downgrades Intel to Neutral, Cuts Price Target to $100
BofA lowered its rating on Intel from Buy to Neutral and reduced its price target from $145 to $100.
M impact | EQUITY | Oct 30, 2026, 12:33 PM UTC
Regeneron Shares Rise More Than 8% Premarket After Q3 Earnings Beat
Regeneron reported stronger-than-expected third-quarter earnings, supported by demand for its eye treatments and higher collaboration revenue from Sanofi. Shares gained more than 8
M impact | EQUITY | Oct 30, 2026, 12:31 PM UTC
European session market picture: S&P 500 -1.1%, Nasdaq 100 -2.59%; EUR/USD +0.1%, WTI +1.86%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 1.1 percent, Nasdaq futures is down 2.59 percent, Dow futures is down 0.1 percent and Russell futures is
M impact | EQUITY | Oct 30, 2026, 12:30 PM UTC
Chevron Reports Q3 2026 Revenue of $67.8 Billion
Chevron reported Q3 2026 revenue of $67.8 billion, up 36.3% year on year, and non-GAAP profit of $5.28 per share, 8.5% above analysts’ consensus estimates.
H impact | EQUITY | Oct 30, 2026, 12:27 PM UTC
Alphabet Shares Fall More Than 12% as Investors Weigh AI Spending
Alphabet reported diluted earnings of $2.12 per share and quarterly revenue of $127.58 billion. Investors focused on rising infrastructure spending and negative free cash flow desp
M impact | EQUITY | Oct 30, 2026, 12:26 PM UTC